

1 **Wnt/PCP signaling mediates breast cancer metastasis by promoting pro-invasive**
2 **protrusion formation in collectively motile leader cells**

3
4 Kacey VanderVorst¹, Courtney A. Dreyer¹, Jason Hatakeyama², George R. R. Bell³, Anastasia L.
5 Berg¹, Maria Hernandez¹, Hyun Lee¹, Sean R. Collins³ and Kermit L. Carraway III^{1*}

6
7 ¹Department of Biochemistry and Molecular Medicine and University of California Davis
8 Comprehensive Cancer Center, University of California Davis School of Medicine, Sacramento,
9 CA, USA

10
11 ²Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of
12 Medicine, Stanford, CA, USA

13
14 ³Department of Microbiology and Molecular Genetics, University of California Davis, Davis, CA,
15 USA

16
17 *To whom correspondence should be addressed: klcarraway@ucdavis.edu

18 **Abstract**

19 As evidence supporting essential roles for collective cell migration in carcinoma metastasis
20 continues to accumulate, a better understanding of the underlying cellular and molecular
21 mechanisms will be critical to translating these findings to the treatment of advanced cancers.
22 Here we report that Wnt/PCP, a non-canonical Wnt signaling pathway, mediates breast cancer
23 collective migration and metastasis. We observe that mammary gland-specific knockout of
24 *Vangl2*, a tetraspanin-like scaffolding protein required for Wnt5a-induced signaling and motility in
25 cultured breast cancer cell lines, results in a striking decrease in metastatic efficiency but not
26 primary tumor growth in the *MMTV-NDL* transgenic mouse model of HER2-positive breast cancer.
27 We also observe that expression levels of core Wnt/PCP components *Wnt5a*, *Vangl1* and *Vangl2*
28 are selectively elevated in K14-positive leader cells relative to follower cells within a collectively
29 migrating cohort, and that *Vangl2* expression selectively promotes RhoA activation in leading
30 edge cells. Moreover, *Vangl* expression drives collective migration in three-dimensional *ex vivo*
31 tumor organoids, and Vangl protein specifically accumulates within pro-migratory filamentous
32 actin-rich protrusions of leader cells. Together, our observations point to a model whereby
33 Wnt/PCP upregulation facilitates breast tumor collective cell motility by selectively augmenting
34 the formation pro-migratory protrusions within leader cells.

35 **Introduction**

36 Metastasis is a complex, multi-step process whereby cancer cells invade into surrounding tissues,
37 access and traverse the vasculature, disseminate throughout the body, and proliferate at
38 secondary sites (Talmadge & Fidler, 2010). Observations that carcinoma cells invade almost
39 exclusively in a collective manner (Bronsert et al., 2014), and that metastatic lesions may be
40 largely seeded by polyclonal cell clusters rather than individual disseminated cells (Aceto et al.,
41 2014; Cheung et al., 2016; Fischer et al., 2015; Hou et al., 2012), strongly suggest that collective
42 cell migration, defined as the coordinated movement of cohorts of cells in sheets or clusters that
43 retain cell-cell contacts (Friedl & Gilmour, 2009), is a major driver of invasiveness and metastasis.
44 In non-transformed tissues, collective cell migration promotes blood vessel formation (Geudens
45 & Gerhardt, 2011), convergent extension (Davey & Moens, 2017), branching morphogenesis
46 (Ewald et al., 2008), and wound healing (Friedl & Gilmour, 2009). However, the study of collective
47 cell migration in carcinomas significantly lags that of classical epithelial-mesenchymal transition
48 (EMT)-mediated motility of individual cells. Thus, a better understanding of cell signaling
49 pathways that govern collective cell migration and invasiveness may identify novel therapeutic
50 targets to intervene in patients with aggressive and late-stage disease.

51

52 We recently proposed a model whereby aberrant activation of Wnt/planar cell polarity (Wnt/PCP)
53 signaling (VanderVorst et al., 2019), a branch of non-canonical Wnt signaling paradoxically critical
54 to both the establishment and maintenance of polarity in epithelial sheets as well as cell migration
55 during embryonic development (Butler & Wallingford, 2017; Caddy et al., 2010), promotes the
56 invasiveness of primary tumor cells. In Wnt/PCP signaling, binding of non-canonical Wnt ligands
57 such as Wnt5a to transmembrane Frizzled (Fzd) receptors initiates polarization signals that are
58 transduced through the essential pathway components Vangl, Dishevelled (Dvl), and Prickle (Pk)
59 (Chu & Sokol, 2016; Minegishi et al., 2017; Wu et al., 2013). Although Dvl and Fzd are required
60 for both canonical and alternative non-canonical Wnt pathways, the unique engagement of Vangl1

61 and Vangl2 transmembrane scaffolds in Wnt/PCP signaling may provide the platform necessary
62 for the assembly of pathway-specific complexes (VanderVorst et al., 2018). Vangl1 and Vangl2
63 are highly similar; their amino acid sequences exhibit 64.3% identity and 78.6% similarity, and no
64 functional biochemical differences have been reported (Hatakeyama et al., 2014). However,
65 Vangl2 alterations result in more profound developmental defects, suggesting a more prominent
66 role for Vangl2 in embryonic tissue organization (Belotti et al., 2012; Hatakeyama et al., 2014).
67 Wnt/PCP signaling is a significant driver of collective cell migration in development (Carmona-
68 Fontaine et al., 2008; Ybot-Gonzalez et al., 2007), and studies employing Looptail (Lp) mice,
69 which harbor point mutations in Vangl2 that alter its trafficking and localization, suggest that Vangl
70 subcellular localization is critical in collectively migrating cells (Murdoch et al., 2001).

71
72 Consistent with observations from developmental studies, Wnt/PCP components mediate cell
73 motility in cancer cells (Asad et al., 2014; Kurayoshi et al., 2006), and core Wnt/PCP components
74 are dysregulated in multiple tumor types, including breast (Anastas et al., 2012; Daulat et al.,
75 2016; Luga et al., 2012; MacMillan et al., 2014; Pukrop et al., 2006; Puvirajesinghe et al., 2016;
76 Zhang et al., 2016), brain (Wald et al., 2017), ovarian (Asad et al., 2014), prostate (Uysal-Onganer
77 et al., 2010), gastric (Kurayoshi et al., 2006), and colorectal cancers (Nishioka et al., 2013; Ueno
78 et al., 2008). We have reported that *VANGL1* and *VANGL2* are respectively upregulated in 5%
79 and 24% of invasive breast carcinomas compared to healthy breast tissue (Hatakeyama et al.,
80 2014), and others have found that elevated *VANGL1* and *VANGL2* are also associated with
81 increased recurrence and decreased metastasis-free survival of breast cancer patients (Anastas
82 et al., 2012; Puvirajesinghe et al., 2016). Together, these observations point to the possibility that
83 aberrant Wnt/PCP activation contributes to breast cancer progression by promoting collective cell
84 migration resulting in metastasis.

85

86 Here we examine the role of Vangl-dependent Wnt/PCP signaling in breast cancer invasiveness
87 and metastasis. We demonstrate that Vangl2 is critical for efficient metastasis but dispensable for
88 primary tumor growth in ErbB2-induced mouse mammary tumors. We further find that Vangl-
89 dependent Wnt/PCP signaling at the leading edge of migrating breast cancer cells results in
90 increased RhoA GTPase activity and formation of pro-migratory protrusions, resulting in collective
91 cell migration *in vitro* and invasion *ex vivo*.


92 **Results**

93 *Vangl2* deletion suppresses mammary tumor metastasis to the lungs but does not alter primary 94 tumor growth

95 We assessed the functional importance of *Vangl2* to mammary tumorigenesis and tumor cell
96 metastatic dissemination by specifically ablating *Vangl2* in the mammary epithelium of *MMTV-*
97 *NDL* mice. In this well-characterized genetically engineered mouse model of breast cancer, an
98 activated ErbB2 mutant encoded by the transgenic rat *c-ErbB2/neu* allele under the control of the
99 MMTV promoter drives the formation of metastatic multifocal mammary tumors at approximately
100 20 weeks of age (Siegel et al., 1999) (Figure 1A). Effective deletion of *Vangl2* in mammary tumors
101 of *Vangl2^{fl/fl}; MMTV-Cre^{+/-}; MMTV-NDL^{+/-}* (*Vangl2^{fl/fl}/NDL*) mice relative to *Vangl2^{fl/fl}; MMTV-NDL^{+/-}*
102 (*Vangl2^{+/+}/NDL*) mice was confirmed by qPCR (Figure 1–figure supplement 1A). Although *Vangl1*
103 may compensate for loss of *Vangl2* in some contexts (Hatakeyama et al., 2014), *Vangl1* transcript
104 is not significantly altered in *Vangl2^{fl/fl}/NDL* mammary tumors relative to *Vangl2^{+/+}/NDL* tumors
105 (Figure 1–figure supplement 1B). *Vangl2* ablation did not produce discernable effects on viability,
106 breeding, or lactation, and no differences in mammary gland architecture were noted between
107 genotypes in adult virgin mammary glands (Figure 1–figure supplement 1C).

108

109 Despite similar kinetics of primary tumor initiation and growth in *Vangl2^{+/+}/NDL* and *Vangl2^{fl/fl}/NDL*
110 mice (Figure 1–figure supplement 2A-D), *Vangl2*-depleted tumors are significantly less metastatic
111 than *Vangl2*-intact tumors (Figure 1B-E). Analysis of lung tissue revealed that deletion of *Vangl2*
112 in *MMTV-NDL* tumors results in significantly reduced frequency of metastatic disease (Figure 1C),
113 number of lung metastases (Figure 1D) and overall metastatic burden (Figure 1E) despite similar
114 primary tumor characteristics such as numbers of palpable tumors (Figure 1F), total tumor volume
115 (Figure 1G), average tumor volume (Figure 1H), tissue histology (Figure 1–figure supplement
116 2E,F), proliferative capacity (Figure 1–figure supplement 2G,H), and apoptosis (Figure 1–figure



118
 119 **Figure 1. Vangl2 deletion suppresses mammary tumor metastasis to the lung.** **A** Summary
 120 of the transgenic mouse strategy employed to assess Vangl2 deletion in mammary tumorigenesis.
 121 **B** Representative images of formalin fixed, paraffin embedded sections from Vangl2^{+/+}/NDL and
 122 Vangl2^{fl/fl}/NDL lung tissue following immunodetection of ErbB2 (top panel) and H&E staining
 123 (bottom panel). Examples of ErbB2-positive metastatic lung lesions are denoted by black
 124 arrowheads, scale bar =500µm. **C-E** Lung lobes (5 lobes per mouse) were evaluated by histology
 125 for the occurrence of metastatic lesions for Vangl2^{+/+}/NDL (*n*=20) and Vangl2^{fl/fl}/NDL tumor-
 126 bearing mice (*n*=20). The number of mice bearing metastatic lesions (**C**), numbers of metastatic
 127 lesions (**D**), and metastatic burden (**E**) were assessed. **F-H** Vangl2/NDL primary tumor growth
 128 characteristics were assessed for Vangl2^{+/+}/NDL (*n*=20) and Vangl2^{fl/fl}/NDL (*n*=20) tumor-bearing
 129 animals, including number of palpable tumors (**F**), total tumor volume (**G**), and average tumor
 130 volume (**H**). Significance was determined by Mann-Whitney test and bar graphs represent the
 131 mean ± sem of experimental replicates (*n*).

132 supplement 2I,J). Importantly, *Vangl2* appears to be critical to successful metastatic colonization
133 of the lungs (Figure 1D,E) but is not required for proliferation of metastatic lesions in
134 *Vangl2^{+/+}/NDL* and *Vangl2^{fl/fl}/NDL* mice (Figure 1–figure supplement 3A,B). Further, cells derived
135 from *Vangl2^{+/+}/NDL* and *Vangl2^{fl/fl}/NDL* tumors injected into the tail veins of FvB/NJ mice exhibit
136 no differences in metastatic lesion colonization efficiency (Figure 1–figure supplement 3C-F).
137 Taken together, these findings suggest that the reduced incidence of metastasis observed upon
138 *Vangl2* ablation is the result of reduced dissemination from the primary tumor rather than
139 suppressed outgrowth of colonies in the lungs. Because Wnt/PCP signaling is vital to collective
140 cell motility events critical to embryonic tissue patterning (Butler & Wallingford, 2017; Hatakeyama
141 et al., 2014), we hypothesized that *Vangl2* facilitates local invasion and migration from the primary
142 tumor, resulting in dissemination and metastatic disease.


143

144 *Vangl2-dependent Wnt/PCP signaling promotes breast cancer cell migration*

145 We interrogated whether loss of *Vangl2* impacts breast cancer cell motility by employing a panel
146 of human breast cancer cell lines encompassing several molecular subtypes: triple-negative
147 BT549, HCC1937, HCC38, MDA-MB-157, MDA-MB-231 and MDA-MB-468, and ER/PR-positive
148 MCF7. Cells were transduced with lentivirus encoding *VANGL2*-targeted shRNAs and knockdown
149 was confirmed by qPCR (Figure 2–figure supplement 1A). Loss of *VANGL2* expression
150 significantly impairs breast cancer cell migration, indicated by the reduced ability of *VANGL2*
151 knockdown cells to migrate into a scratch made in the cellular monolayer (Figure 2A), but does
152 not significantly impair cell proliferation after 12 hours (Figure 2–figure supplement 1B). These
153 data demonstrate that *Vangl2* is critical to breast cancer cell motility, regardless of breast cancer
154 subtype.

155

156 In motile cells, activation of *Vangl*-dependent Wnt/PCP signaling occurs by binding of a non-
157 canonical Wnt ligand such as Wnt5a to Fzd receptors at the plasma membrane, resulting in



160 **Figure 2. Vangl2 is essential for Wnt5a-induced Wnt/PCP signaling and breast cancer cell**
161 **motility. A** Relative cell migration quantification of BT549, HCC1937, HCC38, MCF7, MDA-MB-
162 157, MDA-MB-231, and MDA-MB-468 cells stably expressing Control, shVangl2-1, or shVangl2-
163 2 (BT549 $n=3$, $p=4.81E-05$ and $p=4.47E-05$, HCC1937 $n=4$, $p=0.0002$ and $p=3.37E-05$, HCC38
164 $n=3$, $p=7.69E-06$ and $p=4.31E-05$, MCF7 $n=3$, $p=0.0180$ and $p=0.0004$, MDA-MB-231 $n=4$,
165 $p=0.0001$ and $p=2.73E-05$, MDA-MB-468 $n=4$, $p=0.0046$ and $p=0.0033$). **B** Representative
166 images of migrating NDL cells stimulated with Vector- or Wnt5a- conditioned media at 0 and 12
167 hours. Scale bar = 200 μ m. **C** Relative cell migration quantification of MCF7, MDA-MB-231, MDA-
168 MB-468, and NDL cells stimulated with Vector- or Wnt5a-conditioned media (MCF7 $n=10$,
169 $p=1.54E-08$, MDA-MB-231 $n=4$, $p=0.0006$, MDA-MB-468 $n=9$, $p=2.33E-06$, NDL $n=4$, $p=0.0344$,).
170 **D,E** MCF7, MDA-MB-231, MDA-MB-468, Met-1, and NDL cells stimulated with Vector- or Wnt5a-
171 conditioned media for 1 hour blotted for Dvl2 (**D**) and quantification of relative Dvl2
172 phosphorylation (MCF7 $n=4$, $p=0.0067$, MDA-MB-231 $n=4$, $p=0.0199$, MDA-MB-468 $n=3$,
173 $p=0.0327$, Met-1 $n=3$, $p=0.0121$, NDL $n=8$, $p=0.0007$) (**E**). **F** Relative cell migration quantification
174 of MDA-MB-231 cells stably expressing Control, shVangl2-1, or shVangl2-2 stimulated with
175 Vector- or Wnt5a- conditioned media (control: vector- vs Wnt5a-conditioned media $n=4$,
176 $p=0.0003$, Control vs shVangl2-1 + vector-conditioned media $n=4$, $p=0.0003$, control vs shVangl2-
177 2 + vector-conditioned media $n=4$, $p=0.0003$, shVangl2-1: vector- vs Wnt5a-conditioned media
178 $n=4$, $p=0.7256$, shVangl2-2: vector- vs Wnt5a-conditioned media $n=4$, $p=0.5804$). Bar graphs
179 represent the mean \pm sem of experimental replicates (n). Significance was determined by a two-
180 sided unpaired t -test with Welch's correction, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

181 recruitment and phosphorylation of Dvl. Transmembrane proteins Vangl1 and Vangl2 and
182 activated Dvl may serve as both scaffolds and activators of downstream effector components that
183 mediate context- and tissue-specific actin cytoskeletal rearrangements to promote cellular motility
184 (Wald et al., 2017). Consistent with previous reports (MacMillan et al., 2014), we found that Wnt5a
185 is a potent activator of Wnt/PCP signaling that drives breast cancer cell migration. Stimulation of
186 breast cancer cell lines with Wnt5a-conditioned media enhances cellular migration (Figure 2B,C)
187 and robustly increases phosphorylation of Dvl2 (Figure 2D,E) compared to vector control-
188 conditioned media. To exclude the possibility that Wnt5a activates the canonical Wnt pathway,
189 we assessed phosphorylation of β -catenin, a marker of canonical Wnt signaling (van Amerongen,
190 2012). Stimulation of MCF7 cells with Wnt5a-conditioned media does not significantly impact β -
191 catenin phosphorylation, whereas stimulation with conditioned media containing the potent
192 canonical Wnt activating ligand Wnt3a significantly reduces β -catenin phosphorylation (Figure 2–
193 figure supplement 1C-D). Thus, Wnt5a-dependent migration and Dvl2 phosphorylation in breast
194 cancer cells is driven by engagement of a non-canonical rather than canonical Wnt signaling
195 pathway.

196
197 Dvl2 phosphorylation is also a common feature of other non-canonical Wnt pathways independent
198 of Wnt/PCP signaling (Semenov et al., 2007), and while a downstream effector specific to
199 Wnt/PCP signaling has yet to be identified, this branch of non-canonical Wnt signaling requires
200 the formation of Vangl-dependent complexes (Hatakeyama et al., 2014). We determined that
201 Wnt5a-mediated migration is ablated in *VANGL2* knockdown breast cancer cells (Figure 2F),
202 demonstrating that Wnt5a specifically activates Vangl-dependent Wnt/PCP signaling in breast
203 cancer cells.


204
205 *High Vangl expression aberrantly engages Wnt/PCP signaling and enhances breast cancer cell*
206 *motility*

207 Our observations that Vangl2 mediates mammary tumor metastasis (Figure 1) and is required for
208 Wnt5a-mediated cell migration (Figure 2), combined with previous reports that elevated *VANGL2*
209 expression correlates with worsened metastasis-free survival in breast cancer patients
210 (Puvirajesinghe et al., 2016), suggest that high Vangl expression may result in enhanced cellular
211 migration and aberrant engagement of Wnt/PCP signaling in breast tumors. To investigate this
212 possibility, we stably overexpressed Vangl1 or Vangl2 via lentiviral infection in human and mouse
213 breast tumor cell lines (Figure 3–figure supplement 1A,B). Breast cancer cells overexpressing
214 Vangl1 or Vangl2 exhibit increased motility and Dvl2 phosphorylation compared to cells
215 transduced with control lentivirus (Figure 3A, C-F), and display a distinctive hyper-protrusive
216 leading edge morphology (Figure 3B). These observations indicate that Vangl proteins are
217 sufficient to aberrantly engage Wnt/PCP signaling either independent of Wnt ligand or by
218 potentiating signaling from endogenous Wnt ligand.

219
220 To distinguish between these possibilities, we treated Vangl overexpressing breast cancer cells
221 with the Porcupine antagonist C59, which impairs palmitoylation and subsequent secretion of Wnt
222 ligands (Proffitt et al., 2013), to deplete endogenous Wnt5a ligand. C59 treatment resulted in
223 ablation of Vangl-mediated Dvl2 phosphorylation (Figure 3G,H), demonstrating that aberrant
224 Wnt/PCP signaling mediated by Vangl overexpression is Wnt ligand-dependent. Taken together,
225 these findings suggest that activation of Wnt/PCP signaling in breast cancer cells, accomplished
226 either by exposing cells to elevated levels of non-canonical Wnt ligand or by potentiating signals
227 from endogenous Wnt ligands through overexpression of Vangls, enhances cellular motility and
228 may promote metastatic dissemination of primary tumor cells.

229
230 *Wnt/PCP signaling drives breast carcinoma cell collective invasion*

231 Collective cell invasion is driven by leader cells that aggressively invade while remaining attached
232 to follower cells, resulting in the formation of contiguous invasive strands



235 **Figure 3. Vangl1 overexpression potentiates Wnt/PCP signaling and promotes breast**
236 **cancer cell migration. A,B** Representative brightfield images of migrating NDL cells stably
237 expressing Vector, Vangl1, or Vangl2 at 0 and 12 hours, scale bar = 200 μ m (**A**) and leading-edge
238 dynamics at 12 hours, scale bar = 50 μ m (**B**). **C** Relative cell migration quantification of BT549,
239 MCF7, Met-1, and NDL cells stably expressing Vector or Vangl1 (BT549 $n=5$, $p=0.0001$, MCF7
240 $n=7$, $p=0.0035$, Met-1 $n=3$, $p=0.0339$, NDL $n=6$, $p=0.0108$). **D** Relative cell migration
241 quantification of BT549, MCF7, MDA-MB-231, Met-1, and NDL cells stably expressing Vector or
242 Vangl2 (BT549 $n=3$, $p=0.0210$, MCF7 $n=8$, $p=6.17E-05$, MDA-MB-231 $n=3$, $p=0.0050$, Met-1 $n=3$,
243 $p=0.0412$, NDL $n=8$, $p=0.0049$). **E,F** NDL cells stably expressing Vector, Vangl1 or Vangl2 blotted
244 for Dvl2 (**E**) and quantification of Dvl2 phosphorylation in NDL and Met-1 cells stably expressing
245 Vector, Vangl1 or Vangl2 (**F**) (NDL-Vangl1 $n=3$, $p=0.0291$, NDL-Vangl2 $n=6$, $p=0.0453$, Met-1-
246 Vangl1 $n=5$, $p=0.0009$, Met-1-Vangl1 $n=3$, $p=0.0119$). **G,H** NDL cells stably expressing Vector,
247 Vangl1, or Vangl2 treated with DMSO or 100nM C59 for 24 hours blotted for Dvl2 (**G**) and
248 quantification of relative Dvl2 phosphorylation (**H**). Bar graphs represent the mean \pm sem of
249 experimental replicates (n). Significance was determined by a two-sided unpaired t -test with
250 Welch's correction, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.


251 (Cheung et al., 2013; Cheung et al., 2016; VanderVorst et al., 2019). Invasive leader cells are
252 molecularly and behaviorally distinct from bulk tumor cells, and in some mammary tumor models
253 and human breast tumors express the basal epithelial marker cytokeratin 14 (K14) (Cheung et
254 al., 2013). Importantly, K14-positive leader cells are not enriched for markers of stemness or EMT
255 (Cheung et al., 2013), underscoring the unique character of this population and distinguishing
256 these cells from classically defined invasive mediators of metastasis.

257

258 To investigate the contribution of Wnt/PCP signaling to breast cancer cell collective invasion, we
259 employed an *ex vivo* 3D collagen invasion assay (Nguyen-Ngoc et al., 2012), in which tumor
260 organoids form multicellular epithelial cell protrusions that invade a collagen matrix. Individual
261 tumor cells derived from the highly aggressive, metastatic *MMTV-PyMT* mouse model (Guy et al.,
262 1992; Lin et al., 2003) were first seeded in Matrigel, transduced with lentivirus encoding Wnt/PCP
263 components (Figure 4—figure supplement 1A-C), and cultured for one week to generate tumor
264 organoids. Organoids were then transferred to 3D collagen I gels, a model for the
265 microenvironment surrounding invasive breast cancers (Nguyen-Ngoc et al., 2012), and a fraction
266 of epithelial cells became K14-positive leader cells that formed multicellular protrusions of
267 collectively invading cells upon stimulation with *bFGF* (Cheung et al., 2013).

268

269 We observed that lentiviral-mediated overexpression of *Wnt5a*, *Vangl1*, or *Vangl2* significantly
270 increases the frequency of *bFGF*-dependent collectively invading strands formed by *MMTV-PyMT*
271 organoids (Figure 4A-C). Expression of Wnt/PCP components was not sufficient to stimulate
272 collective invasion in the absence of *bFGF* (Figure 4—figure supplement 1D), indicating that
273 Wnt/PCP signaling cooperates with additional signaling pathways to promote collective invasion
274 rather than independently driving formation of invasive protrusions. Our data suggest that *Vangl1*
275 is highly expressed in K14-positive cells at the tip of invading strands compared to K14-negative
276 follower cells or non-invading tumor organoid cells (Figure 4D), indicating that Wnt/PCP signaling



278 **Figure 4. Wnt/PCP signaling drives collective cell invasion ex vivo and is upregulated in**
279 **the K14-positive leader cell population. A** Representative bright field images of *MMTV-PyMT*-
280 derived mouse mammary tumor organoids stably overexpressing Vector, *Vangl1*, *Vangl2* or
281 *Wnt5a* invading into collagen in the presence of 2.5nm *bFGF*. **B** Quantification of the percentage
282 of organoids counted with 0-2, 3-5, and 6+ collectively invading protrusions for Vector-, *Vangl1*-,
283 *Vangl2*-, or *Wnt5a*-expressing organoids (Vector 547, *Vangl1* 371, *Vangl2* 276, *Wnt5a* 456
284 organoids counted from $n=6$ independent experiments, p -values represent Vector (V) vs *Vangl1*
285 (V1), *Vangl2* (V2), *Wnt5a* (W), 0-2 protrusions; V vs V1 $p=0.0011$, V vs V2 $p=6.32E-06$, V vs W
286 $p=2.50E-05$, 3-5 protrusions; V vs V1 $p=0.0001$, V vs V2 $p=8.94E-05$, V vs W $p=0.0092$, 6+
287 protrusions; V vs V1 $p=0.0027$, V vs V2 $p=0.0132$, V vs W $p=0.0024$). Bar graphs represent the
288 mean \pm sem of experimental replicates (n), significance was determined by a two-sided unpaired
289 t -test, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. **C** Representative confocal images of
290 Vector-, *Vangl1*-, *Vangl2*-, or *Wnt5a*-expressing *PyMT*-derived organoids stained with K14: green,
291 Actin: red, and DAPI: blue. Yellow arrows: K14+ collectively invading protrusion. **D** Representative
292 confocal images of *PyMT*-derived organoids stained with K14: green, *Vangl1*: red, Actin: grey,
293 and DAPI: blue (top) and boxed regions have been expanded to show details (bottom). Yellow
294 arrows: K14+/*Vangl1*+ leader cells of a collectively invading protrusion. **E** Analysis of RNA-
295 sequencing data set SRP066316 from NCBI Sequence Read Archive for *Wnt5a*, *Vangl2*, and
296 *Vangl1* transcript in K14- and K14+ cells derived from *MMTV-PyMT* tumors (*Wnt5a* $p= 7.15E-05$,
297 *Vangl2* $p=0.0049$, *VANGL1* $p=0.0422$), significance was determined by likelihood ratio test
298 followed by Benjamin-Hochberg correction for multiple hypothesis testing. Scale bars=50 μ m.

299 specifically augments the protrusive activity of K14-positive leader cells that drive collective
300 invasion. In support of our findings, analysis of a publicly available dataset that accompanied the
301 foundational study describing the contributions of K14-positive leader cells to breast cancer
302 progression (Cheung et al., 2016) revealed that *Wnt5a*, *Vangl1*, and *Vangl2* transcripts are
303 significantly elevated in the K14-positive tumor cell population (Figure 4E). Other Wnt/PCP
304 component transcripts including noncanonical Frizzled receptors and Dvl were not significantly
305 altered (Figure 4–figure supplement 1E). Taken together, these findings suggest that Wnt/PCP
306 signaling may augment the invasive behavior of K14-positive leader cells and supports a model
307 in which Vangl-mediated Wnt/PCP signaling drives metastatic dissemination through promotion
308 of local collective cell migration and invasion from the primary tumor.

309

310 *Vangl localizes to the leading-edge of collectively migrating breast cancer cells and promotes a*
311 *hyper-protrusive leading-edge*

312 Wnt/PCP signaling is essential for the establishment and maintenance of polarity in epithelial
313 tissues, where it regulates cell polarization in the planar axis across the surface of an epithelial
314 sheet (Devenport, 2014). Planar polarity across the tissue is achieved through the asymmetric
315 distribution of core Wnt/PCP complexes within individual cells reinforced by intracellular
316 antagonism between opposing complexes (Axelrod, 2001; Jenny et al., 2005; Tree et al., 2002;
317 Warrington et al., 2017). Intercellular complexes formed by opposing complexes on adjacent cells
318 then transmit that asymmetry to neighboring cells (Chen et al., 2008; Strutt & Strutt, 2008; Wu &
319 Mlodzik, 2008), and propagation of this asymmetry across many cell distances allows for
320 integration of global cues to locally polarized cellular behavior (Devenport, 2014). However, the
321 requirement for Wnt/PCP complex asymmetry in migrating cancer cells has remained unclear,
322 despite significant effort to understand component localization in migrating breast cancer cells
323 (Anastas et al., 2012; Daulat et al., 2016; Luga et al., 2012).

324


325 We employed immunofluorescence microscopy to assess the localization of endogenous
326 Wnt/PCP components in MCF7 breast cancer cells and cells derived from *MMTV-PyMT* tumors,
327 which migrate as cohesive sheets with E-cadherin-rich cell-cell junctions (Figure 5–figure
328 supplement 1A,B). In MCF7 cells, we observed that both Vangl1 and Fzd7, which typically localize
329 to opposing complexes within planar polarized tissues (VanderVorst et al., 2018), co-localize at
330 actin-rich migratory protrusions in cells at the leading-edge of a collectively migrating cohort
331 (Figure 5A). Consistent with observations that Vangl overexpression enhances cellular motility
332 (Figure 3C,D), Vangl1 overexpression in MCF7 cells elicits a hyper-protrusive leading-edge
333 enriched for Vangl1, Fzd7 and Actin (Figure 5B), suggesting that elevated Vangl1 mediates the
334 assembly of Wnt/PCP complexes that promote the formation of pro-migratory protrusions that
335 drive collective cell migration. Indeed, elevated Vangl1 expression significantly increases both the
336 number of Vangl1-rich protrusions in leader cells and the percentage of leader cells with Vangl1-
337 rich protrusions in a collectively migrating sheet of MCF7 cells (Figure 5–figure supplement 1C,D).
338 We also observed Vangl1-rich protrusions at the leading-edge of collectively migrating primary
339 *MMTV-PyMT* tumor cells migrating as both sheets and clusters (Figure 5C). These data suggest
340 that Vangl mediates the formation of pro-migratory protrusions in collectively migrating breast
341 cancer cells and that high Vangl expression drives enhanced cellular invasiveness through the
342 regulation of aberrant leading-edge protrusion formation.

343


344 *Vangl2 regulates RhoA activity in leader cells of collectively migrating breast cancer cells*

345 Our findings that Vangl drives collective cell motility and invasion as well as mediates the
346 formation of pro-migratory protrusions in leader cells of collectively migrating breast cancer cells
347 led us to question the molecular mechanisms by which Vangl achieves these outcomes. We
348 hypothesized that Vangl may regulate the actin cytoskeleton in leader cells via engagement of
349 Rho GTPases Rac1 and RhoA, which are engaged in Wnt/PCP-mediated motility during
350 vertebrate gastrulation in developing embryos (Habas et al., 2003; Habas et al., 2001). The


A



B



C



352 **Figure 5. Vangl localizes to the leading-edge of leader cells in collectively migrating breast**
353 **cancer cells and promotes a hyper-protrusive morphology. A,B** Representative confocal
354 images of collectively migrating MCF7-Vector cells stained for Vangl1: green, Fzd7: red, Actin:
355 grey, and DAPI: blue **(A)** and MCF7-Flag-Vangl1 cells stained for Flag: green, Fzd7: red, Actin:
356 grey, and DAPI: blue **(B)**, yellow arrows: Vangl1-rich protrusions, scale bar=10 μ m. **C**
357 Representative confocal images of *MMTV-PyMT* tumor-derived cells migrating collectively as a
358 sheet (upper panel) or as a cluster (lower panel) stained for Vangl1: green, Actin: grey, and DAPI:
359 blue. Yellow arrows: Vangl1-rich protrusions in leading-edge cells of migrating sheets and
360 clusters, scale bar=50 μ m.


361 regulation of Rac1 and RhoA GTPase activity is complex and permits context-specific activation
362 of signaling events at specific subcellular localizations with precise kinetics (Ridley, 2015).
363 Unfortunately, previous studies that investigated the ability of Wnt/PCP components to specifically
364 engage and regulate Rho GTPases in cancer cells have predominantly assessed global GTPase
365 activity in lysed cells via GST pull-down assays (Asad et al., 2014; Kurayoshi et al., 2006; Wald
366 et al., 2017), leaving the localization and kinetics of Wnt/PCP-mediated RhoA and Rac1 activity
367 largely unexplored.

368

369 We investigated the spatiotemporal dynamics of GTPase signaling in real time via time-lapse
370 imaging in collectively migrating breast cancer cells by monitoring GTPase activity using stably
371 expressed Rac1 or RhoA fluorescence resonance energy transfer (FRET) biosensors (Yang et
372 al., 2016). Here, MCF7 cells stably expressing non-targeting control shRNA or two independent
373 *VANGL2*-targeted shRNAs and a Rac1 or RhoA biosensor were seeded onto glass-bottom plates,
374 the confluent monolayer was scratched at zero hours, and scratches imaged every fifteen minutes
375 throughout the 12 hour migration assay (Figure 6A, Supplementary Videos 1-3). The mean FRET
376 ratio, which indicates Rac1 or RhoA activity, was measured after 1, 6, and 12 hours of migration
377 and plotted as a function of distance from the leading-edge of the migrating cohort of MCF7 cells
378 using a custom MATLAB script to quantify Rac1 and RhoA activity across the monolayer of cells
379 (Figure 6B, Figure 6–figure supplement 1A). Briefly, our MATLAB script identified the leading-
380 edge of the migrating cohort of MCF7 cells (Figure 6–figure supplement 1B) and binned migrating
381 cells based on their distance from the edge of the scratch (Figure 6–figure supplement 1C).

382

383 Spatial analysis of RhoA activity after one hour of migration revealed that RhoA activity is highest
384 in the leading-edge cells, with activity peaking at approximately 5-10 μ m from edge of the scratch
385 (Figure 6B) in a collectively migrating cohort of MCF7 cells. Indeed, RhoA activity is significantly
386 higher 5 μ m from the edge of the scratch as compared to cells 100 μ m from the edge of the scratch




389 **Figure 6. Vangl2 preferentially regulates RhoA activity in leader cells of collectively**
390 **migrating breast cancer cells. A** Representative spatial activity profiles of RhoA in collectively
391 migrating MCF7 cells stably expressing RhoA-FRET biosensor and Control (top row), shVangl2-
392 1 (middle row), or shVangl2-2 (bottom row) at 1 hour (left column), 6 hours (center column), and
393 12 hours (right column. Color bars indicate the range of RhoA-FRET biosensor ratios. Scale
394 bar=25 μ m. **B** RhoA activity as a function of distance in μ m from the leading-edge of collectively
395 migrating MCF7 cells stably expressing Vector ($n=27$ wells), shVangl2-1 ($n=24$ wells), or
396 shVangl2-2 ($n=25$ wells) at 1, 6, and 12 hours of migration, error bars indicate \pm sem. **C,D** RhoA
397 activity after one hour of migration at 5 μ m (**C**) and 100 μ m (**D**) from the leading-edge of collectively
398 migrating MCF7 cells stably expressing Vector, shVangl2-1 (Vector vs shVangl2-1, 5 μ m $p=0.05$,
399 100 μ m $p=0.1803$), or shVangl2-2 (Vector vs shVangl2-2, 5 μ m $p=0.0271$, 100 μ m $p=0.1094$),
400 significance was determined by a two-sided unpaired t -test.

401 after one hour of migration (Figure 6–figure supplement 1D). MCF7 cells are roughly 20-25 μ m in
402 diameter, thus the elevated RhoA near the scratch edge likely represents leader cells. Depletion
403 of *VANGL2* significantly reduced RhoA activity in leader cells 5 μ m from the edge of the scratch
404 (Figure 6C) and appeared to reduce RhoA activity in follower cells 100 μ m from the edge of the
405 scratch, but did not pass our threshold for statistical significance (Figure 6D) after one hour of
406 migration. Rac1 signaling did not differ spatially within the migrating cohort and modulation of
407 *VANGL2* did not alter Rac1 activity (Figure 6–figure supplement 1A). Collectively, these findings
408 suggest that Vangl2-dependent Wnt/PCP signaling specifically regulates RhoA in leader cells to
409 support actin cytoskeletal rearrangements critical to the formation of pro-migratory protrusions
410 that drive collective migration.

411

412 Mechanistically, our observations demonstrate that Vangl2 acts at the leading edge of collectively
413 migrating cells to prompt the RhoA-dependent cytoskeletal dynamics necessary for pro-migratory
414 cellular protrusion formation (Figure 7). By extension, we propose that the high Vangl expression
415 frequently observed in primary tumors drives aberrant Vangl-dependent Wnt/PCP signaling,
416 resulting in a hyper-protrusive leading-edge that supports invasiveness and ultimate metastatic
417 dissemination.



419

420

421

422

423

Figure 7. Model of Vangl-dependent Wnt/PCP signaling mediating breast cancer cell collective migration and invasion. Vangl2 acts at the leading edge of collectively migrating cells to prompt the RhoA-dependent cytoskeletal dynamics necessary for pro-migratory cellular protrusion formation.

424 **Discussion**

425 Metastatic disease is responsible for the majority of cancer-related deaths (Steeg, 2016), despite
426 significant investment into elucidating molecular drivers of metastasis and identifying
427 opportunities for therapeutic intervention. The acquisition of migratory and invasive behaviors by
428 tumor epithelial cells is a critical step for metastatic dissemination, but the molecular mechanisms
429 underlying this transition remain incompletely described. However, tumor cells commonly
430 reactivate and exploit developmental motility programs to promote malignancy, giving rise to
431 invasiveness, metastasis, and poor patient survival (Friedl & Gilmour, 2009). In this study, we
432 demonstrate that Wnt/PCP signaling, which in embryos promotes cell polarity and motility to
433 regulate proper tissue structuring (Devenport, 2014), drives the collective migration and invasion
434 of breast tumor cells. We show that the Wnt/PCP-specific transmembrane scaffold protein Vangl2
435 is vital for the efficient formation of metastatic lung lesions from ErbB2-driven mammary tumors,
436 and localizes to the leading-edge of cohorts of collectively migrating breast cancer cells where it
437 engages RhoA to drive the formation of pro-migratory protrusions.

438
439 Despite reports that Vangl2 is highly expressed in 25% of invasive breast cancers (Hatakeyama
440 et al., 2014) and that elevated *VANGL2* correlates with advanced stage disease and decreased
441 metastasis-free survival of breast cancer patients (Puvirajesinghe et al., 2016), the functional role
442 of Vangl2 in breast cancer malignancy has remained largely unexplored. Here, we present the
443 novel finding that that Vangl2, a critical component of Wnt/PCP signaling, is vital to efficient
444 metastasis of mouse mammary tumors. Loss of *Vangl2* does not impact the efficiency with which
445 disseminated tumor cells colonize the lung nor the proliferation of established metastatic lesions.
446 We instead find that high Vangl expression drives collective cell migration *in vitro* and collective
447 cell invasion *ex vivo*, and elevated *Vangl1* and *Vangl2* expression in K14-positive invasive leader
448 cells *in vivo*. High Vangl expression results in hyper-protrusive leading-edge morphology within
449 leader cells of collectively migrating cohorts suggesting that Wnt/PCP signaling is critical in

450 promoting the cytoskeletal remodeling necessary for the invasive behavior of primary breast
451 tumor cells. Our data indicate that *Vangl2* contributes to local collective and migration within the
452 primary tumor, consistent with its role in mediating cell motility during embryonic development
453 (Butler & Wallingford, 2017), resulting in increased dissemination from the primary tumor.

454

455 While *Vangl2* is critical for metastasis of *MMTV-NDL* tumors, it is dispensable for both the initiation
456 and growth of the primary tumor. Our observations are consistent with a role for *Vangl2* in
457 mediating cell motility events critical to developing embryos (Butler & Wallingford, 2017;
458 Devenport, 2014), but conflict with a previous report in which shRNA-mediated knockdown of
459 *VANGL2* decreased proliferation of SUM159 and HCC1806 breast cancer cells xenografted into
460 the flanks of NSG mice (Puvirajesinghe et al., 2016). Based on reports that *VANGL2* upregulation
461 is associated with higher grade breast tumors (Puvirajesinghe et al., 2016), we hypothesize that
462 elevated *VANGL2* expression and resulting activation of Wnt/PCP signaling is a feature of late-
463 stage or advanced disease. Because the autochthonous *MMTV-NDL* model recapitulates the full
464 course of breast cancer development beginning from an untransformed mammary epithelial cell,
465 Wnt/PCP signaling may have not yet been aberrantly engaged for the majority of primary tumor
466 growth. Xenograft tumors derived from cell lines models of late-stage breast cancer may more
467 heavily rely upon Wnt/PCP signaling for primary tumor growth. This discrepancy suggests that
468 Wnt/PCP signaling may be a marker that could be used clinically to predict invasive or aggressive
469 breast cancer.

470

471 Our finding that elevated *Vangl* protein mediates phosphorylation of *Dvl2*, a critical effector of
472 downstream Wnt/PCP signaling, led us to speculate that *Vangl* may directly regulate actin
473 cytoskeleton rearrangements in leader cells. Both the Rho GTPases *Rac1* and *RhoA* are essential
474 components of Wnt/PCP signaling-mediated motility during embryonic development (Habas et
475 al., 2003). To investigate Rho GTPase spatiotemporal dynamics during breast cancer collective

476 cell migration, we employed time-lapse microscopy of MCF7 cells stably expressing FRET
477 biosensors for Rac1 and RhoA. We measured the spatial activity of each GTPase as a function
478 of distance from the edge of a scratch in the cellular monolayer throughout a 12-hour scratch
479 migration. We found RhoA activity consistently peaks in leader cells, whereas Rac1 has a more
480 uniform spatial activity pattern across both leader and follower cell populations. Observation of
481 elevated RhoA activity in MCF7 leader cells was somewhat surprising, as leader cells in collective
482 cell migration are generally thought to have high Rac activity at the cell front to coordinate
483 membrane protrusions via branched actin polymerization, while high RhoA activity at the cell rear
484 facilitates acto-myosin based contraction (Karlsson et al., 2009; Mayor & Etienne-Manneville,
485 2016; Zegers & Friedl, 2014). However, spatial patterning of Rac1 and RhoA activity appear to
486 be specific for both cell migration mode and cell type. For example, in individual migrating normal
487 kidney epithelial Ptk1 cells, RhoA plays a central role in driving anterograde actin flows and
488 contractile forces on strong focal adhesions at the cell front, which work to pull the cell forward
489 (Gupton & Waterman-Storer, 2006). In collectively migrating Madin-Darby Canine Kidney (MDCK)
490 cells, thick actin-myosin II cables around the perimeter of protrusive cell collections termed
491 ‘fingers’ and RhoA activity highest in leading-edge cells regulating the acto-myosin cable (Reffay
492 et al., 2014). Future work is required to determine if collectively migrating MCF7 cells, or
493 collectively migrating breast cancer cells more generally, develop acto-myosin cables analogous
494 to MDCK cells.

495
496 Our findings provide substantive insight into the mechanism by which Vangl proteins specifically
497 mediate the formation of pro-migratory protrusions at the leading-edge of leader cells in
498 collectively migrating cohorts. Additionally, these data suggest that Vangl-mediated regulation of
499 RhoA dynamics in leader cells is critical to Wnt/PCP-mediated collective cell migration and
500 invasion. However, the molecular underpinnings of Vangl-mediated RhoA activity within leader
501 cells are not clear. In vertebrate gastrulation, Wnt/PCP signaling appears to drive cellular motility

502 via engagement of Rho family GTPases in a manner that depends on both the cytoplasmic
503 effector Dvl and Daam1, a Formin homology protein that mediates Wnt-induced Dvl-Rho
504 complexes (Habas et al., 2001). While this study did not investigate whether Vangl is a required
505 component of this complex, we speculate that Vangl may serve as a required scaffold upon which
506 the Dvl-Daam1-RhoA complex assembles in leader cells. This is consistent with previous reports
507 suggesting that Vangl may be a master scaffold upon which diverse complexes assemble
508 (Anastas et al., 2012; Puvirajesinghe et al., 2016; Wald et al., 2017). These findings, coupled with
509 our observations that Vangl localizes to leader cells in collectively migrating and invading cohorts
510 and drives the formation of pro-migratory protrusions, suggests that Vangl-RhoA-mediated
511 modulation of the cytoskeleton in leader cells is a significant contributor to the invasive nature and
512 metastatic dissemination of primary tumor cells.

513 **Materials & Methods**

514 **Generation of Vangl2/NDL mice.** All experimental protocols were approved by the IACUC of the
515 University of California, Davis, CA, USA. *Vangl2*^{tm2.1Mdea/J} conditional knockout mice (Copley et
516 al., 2013) (The Jackson Lab, Stock #025174) were crossed with *Tg(MMTV-cre)4Mam/J* mice
517 (Wagner et al., 1997) (The Jackson Lab, Stock #003553) to generate mice with Vangl2 deletion
518 in the mammary gland. The *MMTV-NDL* mouse has been previously described (Siegel et al.,
519 1999). Genotypes were confirmed by polymerase chain reaction in house using primers for
520 Vangl2 (Fwd 5'-CAGAA CTCCTGTCCCTGA-3'; Rev 5'-CTCAGCTAAACCACCTCTGC-3'), Cre
521 (Fwd 5'-GCGGTCTGGCAGTAAAACTATC-3'; Rev 5'-GTGAAACAGCATTGCTGTCACTT-3'),
522 and NDL (Fwd 5'-TTCCGGAACCCACATCAG -3'; Rev 5'- GTTTCCTGCAGCAGCCTA -3').

523

524 **Tumor monitoring and analysis.** Mammary tumors were palpated once or twice weekly in
525 female Vangl2/NDL mice commencing at 16 weeks of age by a single investigator and all palpable
526 tumors were measured by calipers. When the largest tumor reached 2cm in any direction, mice
527 were euthanized by CO₂ asphyxiation and tumors were collected and either fixed in 10% neutral
528 buffered formalin for paraffin embedding and sectioning or further dissociated for *in vitro* analysis.
529 Mice with illnesses arising independent of their tumors that required sacrifice prior to reaching the
530 pre-determined endpoint were excluded from analyses.

531

532 **Histology and Immunohistochemistry.** Histologic analysis of lungs was performed for all mice
533 on study (n=20 per genotype) and for a randomly selected subset of Vangl2^{+/+}/NDL and
534 Vangl2^{fl/fl}/NDL mammary tumors (n=4 per genotype). H&E-stained sections were prepared using
535 previously described methods (Rowson-Hodel et al., 2015). Immunohistochemistry (IHC) was
536 performed as previously described (Rowson-Hodel et al., 2018). An internal negative control (no
537 primary antibody) was included with each assay.

538

539 **Lung metastases analysis.** Lungs were inflated with PBS, fixed in 10% neutral buffered formalin,
540 paraffin embedded, and sectioned for IHC analysis and H&E staining. The number of ErbB2-
541 positive metastatic lesions present on all five lung lobes were counted for all mice on study (n=20
542 per genotype) from images taken on a Keyence BZ-X810 microscope. Metastatic burden was
543 quantified by normalizing the number of metastatic lesions to the total tumor burden.

544
545 **Tail vein injections.** Pooled primary Vangl2^{+/+}/NDL and Vangl2^{fl/fl}/NDL mammary tumors
546 (Vangl2^{+/+}/NDL n=11, Vangl2^{fl/fl}/NDL n=10; 5 x 10⁵ in 200 µL PBS) were instilled to the lateral tail
547 vein of 12-week-old FvB/NJ mice. Lungs were harvested 6-weeks post injection and analyzed for
548 metastatic lesions. Mice were randomly assigned to cohorts and were caged as mixed cohorts.

549
550 **Cell culture and reagents.** BT549, HCC1937, HCC38, MCF7, MDA-MB-157, MDA-MB-231,
551 MDA-MB-468, nMuMG, L-Cells, and L-Cells-Wnt3a, and HEK293T cells were purchased from the
552 American Type Culture Collection (ATCC) and maintained as recommended at 37°C in 10% CO₂
553 in media supplemented with 10% fetal bovine serum (FBS, Genesee Scientific), 1% penicillin-
554 streptomycin (Invitrogen). Met-1 (gifted by A.D. Borowsky) and NDL cells were maintained as
555 previously described (Borowsky et al., 2005; Miller et al., 2008). Prior to use, cell lines were
556 authenticated by short-tandem repeat profiling (Genetics Core Facility; University of Arizona,
557 Tucson, AZ, USA) and tested for mycoplasma contamination by RT-PCR as described (Uphoff &
558 Drexler, 2002, 2004). Antibodies used for immunoblotting, immunofluorescence, and
559 immunohistochemistry are as follows: anti-Dvl2, anti-p-β-Catenin (Ser33/37/Thr41), anti-β-
560 Catenin (Cell Signaling), anti-Tubulin (Sigma), horseradish peroxidase-conjugated goat anti-
561 mouse and goat anti-rabbit secondary antibodies (Bio-Rad), anti-Vangl1 (R&D Systems), anti-
562 Fzd7 (Abcam), anti-Keratin14 (Biolegend), anti-E-Cadherin, anti-Flag and anti-V5 (Cell
563 Signaling), anti-Phalloidin647 (Invitrogen), and AlexaFluor 488-conjugated goat anti-mouse,
564 AlexaFluor 546-conjugated goat anti-rabbit, and Alexa-Fluor 568-conjugated goat anti-chicken

565 secondary antibodies (Invitrogen), and anti-Ki67, anti-c-Caspase3, and anti-ErbB2 (Cell
566 Signaling). Cells were treated with the Wnt-inhibitor C59 at 100nM (R&D Systems).

567

568 **Generation of stable overexpression and knockdown cell lines by lentiviral transduction.**

569 *VANGL2*-targeted shRNA constructs shVangl2-1 (ID: V3LHS_334647 or ID: TRCN0000180101),
570 shVangl2-2 (ID: V3LHS_334648 or TRCN0000417141) (Dharmacon, Sigma-Aldrich), or control
571 vectors pGIPZ (Dharmacon) or pLKO.1 (a gift from David Sabatini, Addgene plasmid #1864;
572 <http://n2t.net/addgene:1864> ; RRID:Addgene_1864) were employed for Vangl2-depletion studies.

573 Stable overexpression cells were created using Vangl1 and Vangl2 plasmids (Harvard PlasmID
574 repository, HsCD00339551 and HsCD00294893) and Wnt5a plasmid that was a gift from Marian
575 Waterman (Addgene plasmid # 35911; <http://n2t.net/addgene:35911> ; RRID:Addgene_35911)
576 subcloned into the control vector pLX304, a gift from David Root (Addgene plasmid # 25890;
577 <http://n2t.net/addgene:25890> ; RRID:Addgene_25890). VSVG-pseudotyped lentivirus was
578 generated by transfecting HEK293T cells with the psPax2 packaging vector. Cells were
579 transduced with 10µg/mL polybrene (Millipore), followed by drug selection with 1µg/mL Puromycin
580 (Sigma-Aldrich) or 4µg/mL Blasticidin (Sigma-Aldrich).

581

582 **Wnt5a and Wnt3a stimulation.** Wnt5a conditioned media was produced by stably transducing
583 nMUMG, MCF7, MDA-MB-231, MDA-MB-468, or NDL cells with Vector- or Wnt5a-containing
584 lentivirus. Vector- or Wnt3a- conditioned media was collected from L-Cell and L-Cell-Wnt3a,
585 respectively. Conditioned media was collected from confluent cell culture plates, cleared of debris
586 by centrifugation, and stored at -80°C.

587

588 **Scratch migration assays.** Confluent monolayers of cells were scratched with a sterile pipette
589 tip and imaged immediately and after twelve hours with an Olympus IX81 microscope with
590 CellSens Entry software. Scratch area was measured using ImageJ (NIH) and the area of the

591 scratch filled in over twelve hours was quantified. Results were normalized to appropriate controls
592 for each assay.

593

594 **Immunoblotting.** Cells were washed with 1X PBS and lysed directly in 2x Laemmli sample buffer.
595 All samples were resolved by SDS-PAGE, transferred to nitrocellulose membranes, and blotted
596 with the indicated antibodies. Immunoblots were developed using Pierce SuperSignal West
597 chemicals (Thermo Fisher) on an AlphaInnotech imaging station and quantified with ImageJ
598 (NIH).

599

600 **Real-time PCR analysis.** RNA was collected using a PureLink RNA MiniKit (Ambion) and
601 converted to cDNA with the High-Capacity cDNA reverse transcription kit (Applied Biosystems).
602 qPCR was conducted in a Bio-Rad CFX96 real-time PCR system using TaqMan gene-specific
603 primer/probe sets (Applied Biosystems) and SsoAdvanced master mix (Bio-Rad). Analysis was
604 conducted using Bio-Rad CFX Manager software and message levels were normalized to
605 GAPDH.

606

607 **Ex vivo 3D organoid invasion assays.** *MMTV-PyMT* tumor samples were a kind gift from Dr.
608 Jason Hatakeyama (Stanford University, Stanford, CA, USA). Tumors were dissociated into single
609 cells as previously described (Diehn et al., 2009) with minor modifications and seeded in Matrigel
610 (Corning) with organoid growth media, which has been previously described (Nguyen-Ngoc et al.,
611 2012). After twenty-four hours in Matrigel, cells were transduced with specified lentivirus and
612 spininfected for one hour at ~500G in a Beckman centrifuge. After seven days in culture, organoids
613 derived from single *MMTV-PyMT* tumor cells were recovered from Matrigel using Cell Recovery
614 Solution (Corning) and embedded into rat-tail collagen I (Thermo Fisher) as previously described
615 (Nguyen-Ngoc et al., 2012). Invasive protrusions were imaged and counted with an Olympus IX81
616 microscope with CellSens Entry software or Zeiss LSM 710 AxioObserver confocal microscope.

617

618 **RNA-seq data mining.** Raw RNAseq reads from Cheung et al., archived as SRP066316 was
619 downloaded from the Sequence Read Archive (Cheung et al., 2016). Reference genome for
620 pseudoalignment was built in Kallisto v0.43.1 from Genome Reference Consortium Mouse Build
621 38 using a k-mer length of 31. Reads were then pseudoaligned to the reference genome using
622 100 bootstraps to estimate error. Differential expression analysis was then performed in R using
623 the DESeq2 package (1.28.1). Biological replicate #3 (SRR291722 and SRR2921727) varied
624 considerably from the other replicates by principal component analysis and expression of key
625 marker genes, and was therefore omitted from the analysis.

626

627 **Immunofluorescence microscopy.** Cells were seeded onto coverslips, fixed with 4%
628 paraformaldehyde, and stained as indicated. PyMT-derived organoids embedded in collagen I
629 were fixed with 4% PFA and stained as indicated. Imaging was conducted on a Zeiss LSM 710
630 AxioObserver confocal microscope or Keyence BZ-X810 microscope. An internal negative control
631 (no primary antibody) was included with each assay. Average number of Vangl1-rich
632 protrusions/cell was quantified by counting the number of Vangl1+ protrusions in leader cells
633 along the leading-edge of a MCF7 cells actively migrating into a scratch made in a confluent
634 monolayer from 4 or 8 independent scratch assays. Percentage of cells with Vangl1-rich
635 protrusions was quantified by counting the number of leader cells with and without Vangl1+
636 protrusions along the leading-edge of MCF7 cells actively migrating into a scratch made in a
637 confluent monolayer from 4 or 8 independent scratch assays.

638

639 **FRET biosensor scratch assay imaging.** Rac1 and RhoA intramolecular FRET biosensors and
640 have been previously described (Itoh et al., 2002). MCF7 cells stably expressing *VANGL2*-
641 targeted shRNAs to deplete Vangl2 were stably transfected with Rac1 or RhoA intramolecular
642 FRET biosensors using PEI transfection reagent. Rac1 or RhoA biosensor expressing cells were

643 sorted with a BD “inFlux” 18-color cell sorter (Becton Dickinson). For all imaging experiments,
644 cells were plated on glass-bottomed 96-well plates (Cellvis) and grown to confluency. Prior to
645 imaging, the monolayers were scratched with a sterile pipette tip, and the media was replaced
646 with Liebovitz-15 (L-15) media, which was made with no riboflavin, folic acid or dyes to reduce
647 autofluorescence from the media supplemented with 2% FBS (UC Davis Biological Media
648 Services). The plates were then transferred to a Nikon Eclipse TI equipped with an OKO Labs
649 cage incubator set to 37 °C. The microscope is controlled by MATLAB (version 2015 A) through
650 Micro-Manager (v 1.6), allowing precise, repeatable experiments. The X & Y stage positions of
651 the scratch were identified by the user and all scratch positions were stored in MATLAB for time
652 lapse imaging. Epifluorescent CFP/YFP FRET images were collected every 15 min for 12 hours
653 using a 20x Nikon Apochromat 0.75 NA objective. Cyan (~440 nm) excitation illumination was
654 provided by the X-Cite XLED1 BLX module, while simultaneous acquisition of FRET images was
655 achieved using dual Andor Zyla 4.2 sCMOS cameras separated by a Cairn TwinCam LS image
656 splitter with a Chroma Technologies dichroic mirror (ZT491rdc) that reflects wavelengths less than
657 502nm to one camera, while passing longer wavelengths to the second camera.

658

659 **Camera and illumination corrections.** The dark-state noise for each camera was empirically
660 measured as described (Bell et al., 2021). In brief, several images were captured without
661 illumination and the microscope light path set to the oculars. The dark-state correction image was
662 generated by taking the median over the stack of dark images. This correction was then
663 subtracted from all experimental images. CFP/YFP FRET ratio images were observed to have a
664 gradient of activity from the top to the bottom of the images. A correction image was developed
665 to remove this gradient as described (Bell et al., 2021). Images of unstimulated, confluent
666 monolayers of MCF7 cells expressing the CFP/YFP FRET sensor were collected. FRET ratio
667 images were generated from raw CFP and YFP images that were processed using our standard
668 analysis pipeline. The median FRET ratio was taken over the stack of images on a pixel-by-pixel

669 basis. Only pixels that overlapped with a cell logical mask were included in the median analysis.
670 To reduce local variability effects and noise, the median image was broken into 24x24 pixel
671 blocks. Next, the median was taken for each block, the resulting image was then smoothed using
672 a gaussian filter (sigma=5) and the image was then resized to match the size of the input image.
673 To apply the correction, experimental FRET ratio images were divided by the ratio correction
674 image.

675

676 **Image alignment, background subtraction, segmentation, and speckle filtering.** All image
677 analysis methods were conducted using MATLAB. CFP/YFP FRET images were aligned using
678 an alignment algorithm as described (Yang et al., 2016). Images were then cropped to ensure
679 equal size. To estimate the background, empty wells containing L-15 media + 2% FBS were
680 imaged with CFP/YFP imaging configurations that were identical to the experimental conditions.
681 Eight empty well frames were collected, and the median was calculated on a per pixel basis over
682 the image stack. The median well background images were then aligned and cropped to match
683 the size of the experimental images. Next, the background mask was determined for the
684 experimental images. To generate the background mask, the experimental images were log
685 transformed to enhance the dimmer cell pixels. The image threshold was then calculated using
686 Otsu's method (Otsu, 1979). The background logical mask was created by finding pixels in the
687 log transformed image below the threshold. Pixels contained in the background mask were used
688 to find the median intensity in both the empty well image and the experimental image. The ratio
689 of the two median intensities was then used to scale the empty well image to match the intensity
690 of the background pixels in the experimental image. Once scaled, the empty well images were
691 subtracted from the experimental images to remove background.

692

693 To segment the cells for further processing, the scaled background image was subtracted from
694 the CFP and YFP images. The CFP and YFP images were added to reduce signal to noise, and
695 the sum image was then used to identify the cell mask and the scratch mask. Because the cell
696 pixels were much brighter than the scratch pixels, the dimmest 0.5% of pixels were subtracted
697 from the sum image, and the minimum pixel intensity value was set to 20 prior to log
698 transformation. The log transformed images were rescaled to a pixel range from the first percentile
699 to the ninetieth percentile and the background vs foreground threshold was identified using Otsu's
700 method. Background pixels were identified below the threshold to create a background logical
701 mask. The background mask was morphologically closed to remove small gaps in the mask.
702 Small objects below 50 pixels in area were removed from the mask and small holes in the mask
703 were filled. The inverse of this mask was used to define the cell mask. Both cell and background
704 masks were saved for additional processing.

705

706 The raw CFP and YFP images from MCF7 cells had small, but very bright puncta. A speckle filter
707 was developed to remove these puncta from the processed CFP and YFP images. The sum
708 image of the two FRET channels was filtered using a Laplacian operator ($\alpha=0.9$) to convert
709 the brightest pixels to the smallest negative pixels. The Laplace filtered image was subtracted
710 from the sum image, effectively making the brightest pixels even brighter. To threshold rare, but
711 bright pixels, the histogram of the image was taken and the intensity value for the first bin with 9
712 or fewer pixels with positive intensity values were used as the threshold. A bright pixel binary
713 mask was created for all pixels above the bright pixel threshold in the sum image. The bright pixel
714 mask was then morphologically closed to connect neighboring pixels, and objects greater than
715 300 pixels were removed. Finally, the FRET reporters are plasma membrane associated, and in
716 some circumstances, were bright enough to be captured by the bright pixel threshold. These
717 objects were more linear as they were essentially tracings of cell edges. To remove these cell
718 membrane objects, the eccentricity for each object was measured. Objects with an eccentricity

719 >0.6 (more linear than circular) were removed from the mask. The speckle mask was then saved
720 for processing the FRET ratio images.

721

722 Finally, to create the FRET ratio images, raw CFP and YFP images were background subtracted
723 using the scaled background image constructed above. For both CFP and YFP images, pixels in
724 the background mask and pixels in the speckle mask were set to NaNs to remove them from
725 further processing. The background subtracted and segmented CFP and YFP images were
726 smoothed with a gaussian filter (sigma=2) and saved for further processing. Next, the FRET ratio
727 was calculated by dividing the YFP image by the CFP image. The ratio correction image
728 described above was then applied to the FRET ratio image. These FRET ratio images were
729 written to movies and exported for later use.

730

731 **Computation of FRET ratios as a function of distance from the scratch edge.** To understand
732 whether cells near the scratch had higher GTPase activity when compared to cells in the
733 monolayer, FRET ratios were measured and binned based on their distance from the scratch
734 edge. To identify the scratch edge, the background masks described above were further
735 analyzed. The scratch is the largest object in the background mask, thus the object with the
736 maximum area was defined as the scratch mask. Next, all other objects in the background mask
737 were removed and the perimeter from the scratch mask was defined. The scratches were
738 consistently generated North to South on the well, thus pixels touching the top and bottom of the
739 perimeter mask image were removed, leaving two scratch edge perimeter masks that
740 corresponded with the left and right sides of the scratch. The scratch edges were then dilated by
741 2 pixels to ensure overlap with the edge of the cell mask defined above. Additionally, the cell
742 masks were separated based on their relative position to the scratch mask (Left or Right). The
743 MATLAB `bwdistgeodesic` function was then used to measure the “quasi-euclidean” distance of all
744 pixels in the left and right cell masks based on their distance from the corresponding scratch edge

745 mask. These distance masks were used to sort pixels into 5 μm bins based on their distance from
746 the scratch edge. The ratio correction image was applied to the YFP images, then the mean
747 intensity values for the background subtracted, and segmented FRET donor and FRET acceptor
748 images were calculated for each bin. The mean FRET ratio for each bin was then calculated.
749 These measurements were compiled for each well within the experimental groups and were used
750 to generate the plots reported.

751

752 **Statistical analysis.** Prism software (GraphPad Software) was used for all statistical analyses.
753 Statistical significance was determined by two-sided unpaired t-test with Welch's correction,
754 paired t-test, Mann-Whitney test, Log-rank test, or likelihood ratio test followed by Benjamin-
755 Hochberg correction for multiple hypothesis testing (indicated in the figure legends). P -values \leq
756 0.05 were considered statistically significant.

757 **Acknowledgements**

758 These studies were supported by NIH grants R01CA230742 (KLC), F31CA210467 (KV),
759 F31CA246900 (CD), F31CA165758 (JH), T32GM099608 (AB), and DP2HD094656 (SRC) and
760 NSF Graduate Research Fellowship 1650042 (GRRB). We thank Henry Ho for discussion,
761 reagents, and critical reading of the manuscript. We are grateful to Jonathan Van Dyke and the
762 UCD Comprehensive Cancer Center Flow Cytometry Shared Resources supported in part by NIH
763 grant P30CA093373 and Gabe Jackman at Keyence for their technical assistance.

764

765 **Author Contributions**

766 K.V., J.H., and K.L.C. contributed to conceptualization; K.V., J.H., G.R.R.B., S.R.C., and K.L.C.
767 contributed to methodology; K.V., C.A.D., G.R.R.B., A.B., M.H., and H.L. contributed to data
768 collection; K.V., C.A.D., J.H., G.R.R.B., S.R.C., and K.L.C. contributed to data analysis and
769 interpretation; S.R.C. and K.L.C. contributed resources; K.V., J.H., G.R.R.B., and K.L.C.
770 contributed to manuscript writing.

771

772 **Competing Interests**

773 The authors declare no competing interests.

774 **References**

- 775 Aceto, N., Bardia, A., Miyamoto, D. T., Donaldson, M. C., Wittner, B. S., Spencer, J. A., Yu, M., Pely, A.,
776 Engstrom, A., Zhu, H., Brannigan, B. W., Kapur, R., Stott, S. L., Shioda, T., Ramaswamy, S., Ting, D.
777 T., Lin, C. P., Toner, M., Haber, D. A., & Maheswaran, S. (2014). Circulating tumor cell clusters are
778 oligoclonal precursors of breast cancer metastasis. *Cell*, *158*(5), 1110-1122.
779 <https://doi.org/10.1016/j.cell.2014.07.013>
- 780 Anastas, J. N., Biechele, T. L., Robitaille, M., Muster, J., Allison, K. H., Angers, S., & Moon, R. T. (2012). A
781 protein complex of SCRIB, NOS1AP and VANGL1 regulates cell polarity and migration, and is
782 associated with breast cancer progression. *Oncogene*, *31*(32), 3696-3708.
783 <https://doi.org/10.1038/onc.2011.528>
- 784 Asad, M., Wong, M. K., Tan, T. Z., Choolani, M., Low, J., Mori, S., Virshup, D., Thiery, J. P., & Huang, R. Y.
785 (2014). FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of
786 non-canonical Wnt/PCP pathway. *Cell Death Dis*, *5*, e1346.
787 <https://doi.org/10.1038/cddis.2014.302>
- 788 Axelrod, J. D. (2001). Unipolar membrane association of Dishevelled mediates Frizzled planar cell
789 polarity signaling. *Genes Dev*, *15*(10), 1182-1187. <https://doi.org/10.1101/gad.890501>
- 790 Bell, G. R. R., Rincón, E., Akdoğan, E., & Collins, S. R. (2021). Optogenetic control of receptors reveals
791 distinct roles for actin- and Cdc42-dependent negative signals in chemotactic signal processing.
792 *bioRxiv*, 2021.2004.2003.438340. <https://doi.org/10.1101/2021.04.03.438340>
- 793 Belotti, E., Puvirajesinghe, T. M., Audebert, S., Baudalet, E., Camoin, L., Pierres, M., Lasvaux, L., Ferracci,
794 G., Montcouquiol, M., & Borg, J. P. (2012). Molecular characterisation of endogenous
795 Vangl2/Vangl1 heteromeric protein complexes. *PLoS One*, *7*(9), e46213.
796 <https://doi.org/10.1371/journal.pone.0046213>
- 797 Borowsky, A. D., Namba, R., Young, L. J., Hunter, K. W., Hodgson, J. G., Tepper, C. G., McGoldrick, E. T.,
798 Muller, W. J., Cardiff, R. D., & Gregg, J. P. (2005). Syngeneic mouse mammary carcinoma cell
799 lines: two closely related cell lines with divergent metastatic behavior. *Clin Exp Metastasis*,
800 *22*(1), 47-59. <https://doi.org/10.1007/s10585-005-2908-5>
- 801 Bronsert, P., Enderle-Ammour, K., Bader, M., Timme, S., Kuehs, M., Csanadi, A., Kayser, G., Kohler, I.,
802 Bausch, D., Hoepfner, J., Hopt, U. T., Keck, T., Stickeler, E., Passlick, B., Schilling, O., Reiss, C. P.,
803 Vashist, Y., Brabletz, T., Berger, J., Lotz, J., Olesch, J., Werner, M., & Wellner, U. F. (2014). Cancer
804 cell invasion and EMT marker expression: a three-dimensional study of the human cancer-host
805 interface. *J Pathol*, *234*(3), 410-422. <https://doi.org/10.1002/path.4416>
- 806 Butler, M. T., & Wallingford, J. B. (2017). Planar cell polarity in development and disease. *Nat Rev Mol*
807 *Cell Biol*, *18*(6), 375-388. <https://doi.org/10.1038/nrm.2017.11>
- 808 Caddy, J., Wilanowski, T., Darido, C., Dworkin, S., Ting, S. B., Zhao, Q., Rank, G., Auden, A., Srivastava, S.,
809 Papenfuss, T. A., Murdoch, J. N., Humbert, P. O., Parekh, V., Boulos, N., Weber, T., Zuo, J.,
810 Cunningham, J. M., & Jane, S. M. (2010). Epidermal wound repair is regulated by the planar cell
811 polarity signaling pathway. *Dev Cell*, *19*(1), 138-147.
812 <https://doi.org/10.1016/j.devcel.2010.06.008>
- 813 Carmona-Fontaine, C., Matthews, H. K., Kuriyama, S., Moreno, M., Dunn, G. A., Parsons, M., Stern, C. D.,
814 & Mayor, R. (2008). Contact inhibition of locomotion in vivo controls neural crest directional
815 migration. *Nature*, *456*(7224), 957-961. <https://doi.org/10.1038/nature07441>
- 816 Chen, W. S., Antic, D., Matis, M., Logan, C. Y., Povelones, M., Anderson, G. A., Nusse, R., & Axelrod, J. D.
817 (2008). Asymmetric homotypic interactions of the atypical cadherin flamingo mediate
818 intercellular polarity signaling. *Cell*, *133*(6), 1093-1105.
819 <https://doi.org/10.1016/j.cell.2008.04.048>


- 820 Cheung, K. J., Gabrielson, E., Werb, Z., & Ewald, A. J. (2013). Collective invasion in breast cancer requires
821 a conserved basal epithelial program. *Cell*, 155(7), 1639-1651.
822 <https://doi.org/10.1016/j.cell.2013.11.029>
- 823 Cheung, K. J., Padmanaban, V., Silvestri, V., Schipper, K., Cohen, J. D., Fairchild, A. N., Gorin, M. A.,
824 Verdone, J. E., Pienta, K. J., Bader, J. S., & Ewald, A. J. (2016). Polyclonal breast cancer
825 metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. *Proc*
826 *Natl Acad Sci U S A*, 113(7), E854-863. <https://doi.org/10.1073/pnas.1508541113>
- 827 Chu, C. W., & Sokol, S. Y. (2016). Wnt proteins can direct planar cell polarity in vertebrate ectoderm.
828 *Elife*, 5. <https://doi.org/10.7554/eLife.16463>
- 829 Copley, C. O., Duncan, J. S., Liu, C., Cheng, H., & Deans, M. R. (2013). Postnatal refinement of auditory
830 hair cell planar polarity deficits occurs in the absence of Vangl2. *J Neurosci*, 33(35), 14001-
831 14016. <https://doi.org/10.1523/JNEUROSCI.1307-13.2013>
- 832 Daulat, A. M., Bertucci, F., Audebert, S., Serge, A., Finetti, P., Josselin, E., Castellano, R., Birnbaum, D.,
833 Angers, S., & Borg, J. P. (2016). PRICKLE1 Contributes to Cancer Cell Dissemination through Its
834 Interaction with mTORC2. *Dev Cell*, 37(4), 311-325.
835 <https://doi.org/10.1016/j.devcel.2016.04.011>
- 836 Davey, C. F., & Moens, C. B. (2017). Planar cell polarity in moving cells: think globally, act locally.
837 *Development*, 144(2), 187-200. <https://doi.org/10.1242/dev.122804>
- 838 Devenport, D. (2014). The cell biology of planar cell polarity. *J Cell Biol*, 207(2), 171-179.
839 <https://doi.org/10.1083/jcb.201408039>
- 840 Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E.,
841 Wong, M., Joshua, B., Kaplan, M. J., Wapnir, I., Dirbas, F. M., Somlo, G., Garberoglio, C., Paz, B.,
842 Shen, J., Lau, S. K., Quake, S. R., Brown, J. M., Weissman, I. L., & Clarke, M. F. (2009). Association
843 of reactive oxygen species levels and radioresistance in cancer stem cells. *Nature*, 458(7239),
844 780-783. <https://doi.org/10.1038/nature07733>
- 845 Ewald, A. J., Brenot, A., Duong, M., Chan, B. S., & Werb, Z. (2008). Collective Epithelial Migration and Cell
846 Rearrangements Drive Mammary Branching Morphogenesis. *Developmental Cell*, 14(4), 570-
847 581. <https://doi.org/https://doi.org/10.1016/j.devcel.2008.03.003>
- 848 Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T., Choi, H., El Rayes, T., Ryu, S., Troeger, J.,
849 Schwabe, R. F., Vahdat, L. T., Altorki, N. K., Mittal, V., & Gao, D. (2015). Epithelial-to-
850 mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.
851 *Nature*, 527(7579), 472-476. <https://doi.org/10.1038/nature15748>
- 852 Friedl, P., & Gilmour, D. (2009). Collective cell migration in morphogenesis, regeneration and cancer
853 [Review Article]. *Nature Reviews Molecular Cell Biology*, 10, 445.
854 <https://doi.org/10.1038/nrm2720>
- 855 Geudens, I., & Gerhardt, H. (2011). Coordinating cell behaviour during blood vessel formation.
856 *Development*, 138(21), 4569-4583. <https://doi.org/10.1242/dev.062323>
- 857 Gupton, S. L., & Waterman-Storer, C. M. (2006). Spatiotemporal feedback between actomyosin and
858 focal-adhesion systems optimizes rapid cell migration. *Cell*, 125(7), 1361-1374.
859 <https://doi.org/10.1016/j.cell.2006.05.029>
- 860 Guy, C. T., Cardiff, R. D., & Muller, W. J. (1992). Induction of mammary tumors by expression of
861 polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. *Mol Cell*
862 *Biol*, 12(3), 954-961. <https://doi.org/10.1128/mcb.12.3.954>
- 863 Habas, R., Dawid, I. B., & He, X. (2003). Coactivation of Rac and Rho by Wnt/Frizzled signaling is required
864 for vertebrate gastrulation. *Genes Dev*, 17(2), 295-309. <https://doi.org/10.1101/gad.1022203>
- 865 Habas, R., Kato, Y., & He, X. (2001). Wnt/Frizzled activation of Rho regulates vertebrate gastrulation and
866 requires a novel Formin homology protein Daam1. *Cell*, 107(7), 843-854.
867 [https://doi.org/10.1016/s0092-8674\(01\)00614-6](https://doi.org/10.1016/s0092-8674(01)00614-6)

- 868 Hatakeyama, J., Wald, J. H., Printsev, I., Ho, H. Y., & Carraway, K. L., 3rd. (2014). Vangl1 and Vangl2:
869 planar cell polarity components with a developing role in cancer. *Endocr Relat Cancer*, 21(5),
870 R345-356. <https://doi.org/10.1530/ERC-14-0141>
- 871 Hou, J. M., Krebs, M. G., Lancashire, L., Sloane, R., Backen, A., Swain, R. K., Priest, L. J., Greystoke, A.,
872 Zhou, C., Morris, K., Ward, T., Blackhall, F. H., & Dive, C. (2012). Clinical significance and
873 molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients
874 with small-cell lung cancer. *J Clin Oncol*, 30(5), 525-532.
875 <https://doi.org/10.1200/JCO.2010.33.3716>
- 876 Itoh, R. E., Kurokawa, K., Ohba, Y., Yoshizaki, H., Mochizuki, N., & Matsuda, M. (2002). Activation of rac
877 and cdc42 video imaged by fluorescent resonance energy transfer-based single-molecule probes
878 in the membrane of living cells. *Mol Cell Biol*, 22(18), 6582-6591.
879 <https://doi.org/10.1128/mcb.22.18.6582-6591.2002>
- 880 Jenny, A., Reynolds-Kenneally, J., Das, G., Burnett, M., & Mlodzik, M. (2005). Diego and Prickle regulate
881 Frizzled planar cell polarity signalling by competing for Dishevelled binding. *Nat Cell Biol*, 7(7),
882 691-697. <https://doi.org/10.1038/ncb1271>
- 883 Karlsson, R., Pedersen, E. D., Wang, Z., & Brakebusch, C. (2009). Rho GTPase function in tumorigenesis.
884 *Biochim Biophys Acta*, 1796(2), 91-98. <https://doi.org/10.1016/j.bbcan.2009.03.003>
- 885 Kurayoshi, M., Oue, N., Yamamoto, H., Kishida, M., Inoue, A., Asahara, T., Yasui, W., & Kikuchi, A. (2006).
886 Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell
887 migration and invasion. *Cancer Res*, 66(21), 10439-10448. <https://doi.org/10.1158/0008-5472.CAN-06-2359>
- 889 Lin, E. Y., Jones, J. G., Li, P., Zhu, L., Whitney, K. D., Muller, W. J., & Pollard, J. W. (2003). Progression to
890 malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable
891 model for human diseases. *Am J Pathol*, 163(5), 2113-2126. [https://doi.org/10.1016/S0002-9440\(10\)63568-7](https://doi.org/10.1016/S0002-9440(10)63568-7)
- 893 Luga, V., Zhang, L., Vitoria-Petit, A. M., Ogunjimi, A. A., Inanlou, M. R., Chiu, E., Buchanan, M., Hosein, A.
894 N., Basik, M., & Wrana, J. L. (2012). Exosomes mediate stromal mobilization of autocrine Wnt-
895 PCP signaling in breast cancer cell migration. *Cell*, 151(7), 1542-1556.
896 <https://doi.org/10.1016/j.cell.2012.11.024>
- 897 MacMillan, C. D., Leong, H. S., Dales, D. W., Robertson, A. E., Lewis, J. D., Chambers, A. F., & Tuck, A. B.
898 (2014). Stage of breast cancer progression influences cellular response to activation of the
899 WNT/planar cell polarity pathway. *Sci Rep*, 4, 6315. <https://doi.org/10.1038/srep06315>
- 900 Mayor, R., & Etienne-Manneville, S. (2016). The front and rear of collective cell migration. *Nat Rev Mol*
901 *Cell Biol*, 17(2), 97-109. <https://doi.org/10.1038/nrm.2015.14>
- 902 Miller, J. K., Shattuck, D. L., Ingalla, E. Q., Yen, L., Borowsky, A. D., Young, L. J., Cardiff, R. D., Carraway, K.
903 L., 3rd, & Sweeney, C. (2008). Suppression of the negative regulator LRIG1 contributes to ErbB2
904 overexpression in breast cancer. *Cancer Res*, 68(20), 8286-8294. <https://doi.org/10.1158/0008-5472.CAN-07-6316>
- 906 Minegishi, K., Hashimoto, M., Ajima, R., Takaoka, K., Shinohara, K., Ikawa, Y., Nishimura, H., McMahon,
907 A. P., Willert, K., Okada, Y., Sasaki, H., Shi, D., Fujimori, T., Ohtsuka, T., Igarashi, Y., Yamaguchi, T.
908 P., Shimono, A., Shiratori, H., & Hamada, H. (2017). A Wnt5 Activity Asymmetry and Intercellular
909 Signaling via PCP Proteins Polarize Node Cells for Left-Right Symmetry Breaking. *Dev Cell*, 40(5),
910 439-452 e434. <https://doi.org/10.1016/j.devcel.2017.02.010>
- 911 Murdoch, J. N., Doudney, K., Paternotte, C., Copp, A. J., & Stanier, P. (2001). Severe neural tube defects
912 in the loop-tail mouse result from mutation of Lpp1, a novel gene involved in floor plate
913 specification. *Hum Mol Genet*, 10(22), 2593-2601. <https://doi.org/10.1093/hmg/10.22.2593>
- 914 Nguyen-Ngoc, K. V., Cheung, K. J., Brenot, A., Shamir, E. R., Gray, R. S., Hines, W. C., Yaswen, P., Werb, Z.,
915 & Ewald, A. J. (2012). ECM microenvironment regulates collective migration and local

- 916 dissemination in normal and malignant mammary epithelium. *Proc Natl Acad Sci U S A*, 109(39),
917 E2595-2604. <https://doi.org/10.1073/pnas.1212834109>
- 918 Nishioka, M., Ueno, K., Hazama, S., Okada, T., Sakai, K., Suehiro, Y., Okayama, N., Hirata, H., Oka, M.,
919 Imai, K., Dahiya, R., & Hinoda, Y. (2013). Possible involvement of Wnt11 in colorectal cancer
920 progression. *Mol Carcinog*, 52(3), 207-217. <https://doi.org/10.1002/mc.21845>
- 921 Otsu, N. (1979). A Threshold Selection Method for Gray-Level Histograms. *Transactions on Systems,*
922 *Man, and Cybernetics*, SMC-9(1), 62-66.
- 923 Proffitt, K. D., Madan, B., Ke, Z., Pendharkar, V., Ding, L., Lee, M. A., Hannoush, R. N., & Virshup, D. M.
924 (2013). Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-
925 driven mammary cancer. *Cancer Res*, 73(2), 502-507. <https://doi.org/10.1158/0008-5472.CAN-12-2258>
- 926
- 927 Pukrop, T., Klemm, F., Hagemann, T., Gradl, D., Schulz, M., Siemes, S., Trumper, L., & Binder, C. (2006).
928 Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. *Proc Natl*
929 *Acad Sci U S A*, 103(14), 5454-5459. <https://doi.org/10.1073/pnas.0509703103>
- 930 Puvirajesinghe, T. M., Bertucci, F., Jain, A., Scerbo, P., Belotti, E., Audebert, S., Sebbagh, M., Lopez, M.,
931 Brech, A., Finetti, P., Charafe-Jauffret, E., Chaffanet, M., Castellano, R., Restouin, A., Marchetto,
932 S., Collette, Y., Goncalves, A., Macara, I., Birnbaum, D., Kodjabachian, L., Johansen, T., & Borg, J.
933 P. (2016). Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK
934 signalling in breast cancer. *Nat Commun*, 7, 10318. <https://doi.org/10.1038/ncomms10318>
- 935 Reffay, M., Parrini, M. C., Cochet-Escartin, O., Ladoux, B., Buguin, A., Coscoy, S., Amblard, F., Camonis, J.,
936 & Silberzan, P. (2014). Interplay of RhoA and mechanical forces in collective cell migration driven
937 by leader cells. *Nat Cell Biol*, 16(3), 217-223. <https://doi.org/10.1038/ncb2917>
- 938 Ridley, A. J. (2015). Rho GTPase signalling in cell migration. *Curr Opin Cell Biol*, 36, 103-112.
939 <https://doi.org/10.1016/j.ceb.2015.08.005>
- 940 Rowson-Hodel, A. R., Manjarin, R., Trott, J. F., Cardiff, R. D., Borowsky, A. D., & Hovey, R. C. (2015).
941 Neoplastic transformation of porcine mammary epithelial cells in vitro and tumor formation in
942 vivo. *BMC Cancer*, 15, 562. <https://doi.org/10.1186/s12885-015-1572-7>
- 943 Rowson-Hodel, A. R., Wald, J. H., Hatakeyama, J., O'Neal, W. K., Stonebraker, J. R., VanderVorst, K.,
944 Saldana, M. J., Borowsky, A. D., Sweeney, C., & Carraway, K. L., 3rd. (2018). Membrane Mucin
945 Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a
946 mouse model of breast cancer. *Oncogene*, 37(2), 197-207.
947 <https://doi.org/10.1038/onc.2017.327>
- 948 Semenov, M. V., Habas, R., Macdonald, B. T., & He, X. (2007). SnapShot: Noncanonical Wnt Signaling
949 Pathways. *Cell*, 131(7), 1378. <https://doi.org/10.1016/j.cell.2007.12.011>
- 950 Siegel, P. M., Ryan, E. D., Cardiff, R. D., & Muller, W. J. (1999). Elevated expression of activated forms of
951 Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice:
952 implications for human breast cancer. *EMBO J*, 18(8), 2149-2164.
953 <https://doi.org/10.1093/emboj/18.8.2149>
- 954 Steeg, P. S. (2016). Targeting metastasis. *Nat Rev Cancer*, 16(4), 201-218.
955 <https://doi.org/10.1038/nrc.2016.25>
- 956 Strutt, H., & Strutt, D. (2008). Differential stability of flamingo protein complexes underlies the
957 establishment of planar polarity. *Curr Biol*, 18(20), 1555-1564.
958 <https://doi.org/10.1016/j.cub.2008.08.063>
- 959 Talmadge, J. E., & Fidler, I. J. (2010). AACR centennial series: the biology of cancer metastasis: historical
960 perspective. *Cancer Res*, 70(14), 5649-5669. <https://doi.org/10.1158/0008-5472.CAN-10-1040>
- 961 Tree, D. R., Shulman, J. M., Rousset, R., Scott, M. P., Gubb, D., & Axelrod, J. D. (2002). Prickle mediates
962 feedback amplification to generate asymmetric planar cell polarity signaling. *Cell*, 109(3), 371-
963 381. <https://www.ncbi.nlm.nih.gov/pubmed/12015986>

- 964 Ueno, K., Hiura, M., Suehiro, Y., Hazama, S., Hirata, H., Oka, M., Imai, K., Dahiya, R., & Hinoda, Y. (2008).
965 Frizzled-7 as a potential therapeutic target in colorectal cancer. *Neoplasia*, *10*(7), 697-705.
966 <https://www.ncbi.nlm.nih.gov/pubmed/18592008>
- 967 Uphoff, C. C., & Drexler, H. G. (2002). Comparative PCR analysis for detection of mycoplasma infections
968 in continuous cell lines. *In Vitro Cell Dev Biol Anim*, *38*(2), 79-85. [https://doi.org/10.1290/1071-](https://doi.org/10.1290/1071-2690(2002)038<0079:CPAFDO>2.0.CO;2)
969 [2690\(2002\)038<0079:CPAFDO>2.0.CO;2](https://doi.org/10.1290/1071-2690(2002)038<0079:CPAFDO>2.0.CO;2)
- 970 Uphoff, C. C., & Drexler, H. G. (2004). Detecting Mycoplasma contamination in cell cultures by
971 polymerase chain reaction. *Methods Mol Med*, *88*, 319-326. [https://doi.org/10.1385/1-59259-](https://doi.org/10.1385/1-59259-406-9:319)
972 [406-9:319](https://doi.org/10.1385/1-59259-406-9:319)
- 973 Uysal-Onganer, P., Kawano, Y., Caro, M., Walker, M. M., Diez, S., Darrington, R. S., Waxman, J., & Kypta,
974 R. M. (2010). Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of
975 prostate cancer cells. *Mol Cancer*, *9*, 55. <https://doi.org/10.1186/1476-4598-9-55>
- 976 van Amerongen, R. (2012). Alternative Wnt pathways and receptors. *Cold Spring Harb Perspect Biol*,
977 *4*(10). <https://doi.org/10.1101/cshperspect.a007914>
- 978 VanderVorst, K., Dreyer, C. A., Konopelski, S. E., Lee, H., Ho, H. H., & Carraway, K. L., 3rd. (2019).
979 Wnt/PCP Signaling Contribution to Carcinoma Collective Cell Migration and Metastasis. *Cancer*
980 *Res*, *79*(8), 1719-1729. <https://doi.org/10.1158/0008-5472.CAN-18-2757>
- 981 VanderVorst, K., Hatakeyama, J., Berg, A., Lee, H., & Carraway, K. L., 3rd. (2018). Cellular and molecular
982 mechanisms underlying planar cell polarity pathway contributions to cancer malignancy. *Semin*
983 *Cell Dev Biol*, *81*, 78-87. <https://doi.org/10.1016/j.semcdb.2017.09.026>
- 984 Wagner, K. U., Wall, R. J., St-Onge, L., Gruss, P., Wynshaw-Boris, A., Garrett, L., Li, M., Furth, P. A., &
985 Hennighausen, L. (1997). Cre-mediated gene deletion in the mammary gland. *Nucleic Acids Res*,
986 *25*(21), 4323-4330. <https://doi.org/10.1093/nar/25.21.4323>
- 987 Wald, J. H., Hatakeyama, J., Printsev, I., Cuevas, A., Fry, W. H. D., Saldana, M. J., VanderVorst, K.,
988 Rowson-Hodel, A., Angelastro, J. M., Sweeney, C., & Carraway Rd, K. L. (2017). Suppression of
989 planar cell polarity signaling and migration in glioblastoma by Nrpd1-mediated Dvl
990 polyubiquitination. *Oncogene*. <https://doi.org/10.1038/onc.2017.126>
- 991 Warrington, S. J., Strutt, H., Fisher, K. H., & Strutt, D. (2017). A Dual Function for Prickle in Regulating
992 Frizzled Stability during Feedback-Dependent Amplification of Planar Polarity. *Curr Biol*, *27*(18),
993 2784-2797 e2783. <https://doi.org/10.1016/j.cub.2017.08.016>
- 994 Wu, J., & Mlodzik, M. (2008). The frizzled extracellular domain is a ligand for Van Gogh/Stbm during
995 nonautonomous planar cell polarity signaling. *Dev Cell*, *15*(3), 462-469.
996 <https://doi.org/10.1016/j.devcel.2008.08.004>
- 997 Wu, J., Roman, A. C., Carvajal-Gonzalez, J. M., & Mlodzik, M. (2013). Wg and Wnt4 provide long-range
998 directional input to planar cell polarity orientation in Drosophila. *Nat Cell Biol*, *15*(9), 1045-1055.
999 <https://doi.org/10.1038/ncb2806>
- 1000 Yang, H. W., Collins, S. R., & Meyer, T. (2016). Locally excitable Cdc42 signals steer cells during
1001 chemotaxis. *Nat Cell Biol*, *18*(2), 191-201. <https://doi.org/10.1038/ncb3292>
- 1002 Ybot-Gonzalez, P., Savery, D., Gerrelli, D., Signore, M., Mitchell, C. E., Faux, C. H., Greene, N. D., & Copp,
1003 A. J. (2007). Convergent extension, planar-cell-polarity signalling and initiation of mouse neural
1004 tube closure. *Development*, *134*(4), 789-799. <https://doi.org/10.1242/dev.000380>
- 1005 Zegers, M. M., & Friedl, P. (2014). Rho GTPases in collective cell migration. *Small GTPases*, *5*, e28997.
1006 <https://doi.org/10.4161/sgtp.28997>
- 1007 Zhang, L., Luga, V., Armitage, S. K., Musiol, M., Won, A., Yip, C. M., Plotnikov, S. V., & Wrana, J. L. (2016).
1008 A lateral signalling pathway coordinates shape volatility during cell migration. *Nat Commun*, *7*,
1009 11714. <https://doi.org/10.1038/ncomms11714>
- 1010
1011


1012 SUPPLEMENTARY FIGURES and LEGENDS



1014


1015 **Figure 1–figure supplement 1. Functional Vangl2 deletion is evident by transcript. a-b**
1016 **VANGL2 (A) and VANGL1 (B)** transcript from Vangl2^{fl/fl}/NDL and Vangl2^{+/+}/NDL primary tumors
1017 by *q*PCR from three tumors of independent biological sources per genotype. **c** Carmine alum
1018 stained mammary whole mounts from estrus matched 20-week-old Vangl2^{+/+} and Vangl2^{fl/fl} mice,
1019 demonstrating no detectable differences in gland architecture in adult virgin mice. Scale bars =
1020 1mm (top panels) or 500μm (bottom panels).

1021



1023 **Figure 1–figure supplement 2. Vangl2 deletion does not impact primary tumor growth**
1024 **characteristics or histology. A-D** Survival curves and bar graphs depicting Vangl2/NDL tumor
1025 initiation and growth characteristics. Probability of survival **(A)**, tumor latency **(B)**, number of
1026 glands with tumors **(C)**, and tumor growth rate **(D)** for Vangl2^{+/+}/NDL ($n=20$) and Vangl2^{fl/fl}/NDL
1027 ($n=20$) tumor-bearing animals. **E,F** Representative images are depicted of formalin fixed, paraffin
1028 embedded sections from Vangl2^{+/+}/NDL and Vangl2^{fl/fl}/NDL primary tumors stained with H&E **(E)**
1029 or following immunodetection with ErbB2 **(F)**, scale bar=200 μ m. **G-J** Representative images of
1030 Vangl2^{+/+}/NDL and Vangl2^{fl/fl}/NDL primary tumor tissues following immunodetection of
1031 proliferation marker Ki67 **(G)** with quantification of Ki67-positive cells ($n=4$) **(H)** and apoptosis
1032 marker cleaved caspase-3 **(I)** with quantification of c-Caspase 3-positive cells ($n=4$) **(J)**, scale
1033 bar=100 μ m. Significance determined by Log-rank **(A)** or Mann-Whitney test **(C,D)** or two-sided
1034 unpaired *t*-test with Welch's correction **(H,J)**. All bar graphs represent the mean \pm sem of
1035 experimental replicates (n).


1036



1038

1039 **Figure 1–figure supplement 3. Vangl2 is dispensable for metastatic lesion colonization and**
1040 **proliferation. A,B** Metastatic lung lesions of Vangl2^{+/+}/NDL (*n*=4) and Vangl2^{fl/fl}/NDL tumor-
1041 bearing mice (*n*=4) were evaluated for proliferative capacity by immunodetection of Ki67 (**A**) and
1042 the percentage of Ki67-positive cells was quantified (**B**). **C** Representative images of formalin
1043 fixed, paraffin embedded sections of lungs from FvB/NJ mice receiving Vangl2^{+/+}/NDL or
1044 Vangl2^{fl/fl}/NDL cells via the tail vein following immunodetection of ErbB2 (top panel) and H&E
1045 staining (bottom panel). Examples of ErbB2-positive metastatic lung lesions are denoted by black
1046 arrowheads, scale bar =500µm. **D-F** Lung lobes (5 lobes per mouse) from FvB/NJ mice receiving
1047 Vangl2^{+/+}/NDL or Vangl2^{fl/fl}/NDL cells via the tail vein were evaluated by histology for the
1048 occurrence of metastatic lesions for Vangl2^{+/+}/NDL (*n*=11) and Vangl2^{fl/fl}/NDL (*n*=10) cohorts. The
1049 number of mice bearing metastatic lesions (**D**), numbers of metastatic lesions (**E**), and numbers
1050 of lung lobes involved (**F**) were assessed. Significance was determined by Mann-Whitney test
1051 and bar graphs represent the mean ± sem of experimental replicates (*n*).


1052




1054 **Figure 2–figure supplement 1. Supporting materials for Figure 2.** **A** Relative VANGL2
 1055 transcript in BT549, HCC1937, HCC38, MCF7, MDA-MB-231, and MDA-MB-468 stably
 1056 expressing Control, shVangl2-1, or shVangl2-2 by *q*-PCR. **B** Quantification of relative cell
 1057 proliferation of MCF7 cells stably expressing Control, shVangl2-1, or shVangl2-2 ($n=4$). **C,D**
 1058 MCF7 cells stimulated with Vector- or Wnt5a-conditioned media or Vector- or Wnt3a-conditioned
 1059 media for 1 hour blotted for β -Catenin and phospho- β -Catenin (Ser33/37/Thr41) (**C**) and
 1060 quantification of relative phospho- β -Catenin (Ser33/37/Thr41) (control- vs Wnt5a-conditioned
 1061 media $n=6$, $p=0.5419$, control- vs Wnt3a-conditioned media $n=4$, $p=0.0038$) (**D**). Bar graphs
 1062 represent the mean \pm sem of experimental replicates (n). Significance was determined by a two-
 1063 sided unpaired *t*-test with Welch's correction, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

1064

A




B




1066 **Figure 3—figure supplement 1. Overexpression of Wnt/PCP components. A,B** Breast cancer
1067 cell lines stably overexpressing Flag-Vangl1 blotted for Flag (**A**) or V5-Vangl2 blotted for V5 (**B**).

1068




1070 **Figure 4–figure supplement 1. Supporting materials for Figure 4. A-C** *MMTV-PyMT*-derived
1071 tumor organoid cells stably overexpressing Vangl1, Vangl2, or Wnt5a were assessed for Flag-
1072 Vangl1 **(A)** or V5-Vangl2 **(B)** expression by Western blot or *WNT5A* transcript by qPCR **(C)**. **D**
1073 Representative images of Vector-, Vangl1-, Vangl2-, and Wnt5a-expressing *MMTV-PyMT*-
1074 derived tumor organoids in collagen in the absence of *bFGF*, scale bar=50µm. **E** Analysis of RNA-
1075 sequencing data set SRP066316 from NCBI Sequence Read Archive for *Fzd7*, *Fzd6*, *Fzd3*, *Dvl1*,
1076 *Dvl2*, and *Dvl3* transcript in K14-negative and K14-positive cells derived from *MMTV-PyMT*
1077 tumors.

1078



1080 **Figure 5–figure supplement 1. Supporting materials for Figure 5.** A,B Representative
1081 confocal images of collectively migrating MCF7 (A) and MMTV-PyMT tumor-derived (B)
1082 cells stained for E-Cadherin: orange and DAPI: blue, scale bar = 50 μ m. C Quantification of the average
1083 number of Vangl1-rich protrusions per leading-edge cell in collectively migrating MCF7-Vector
1084 and MCF7-Flag-Vangl1 cells (MCF7-Vector $n=8$ scratches quantified, MCF7-Flag-Vangl1 $n=4$
1085 scratches quantified, $p=0.0038$) D Quantification of the percentage of leading-edge cells with
1086 Vangl1-rich protrusions (MCF7-Vector $n=8$, MCF7-Flag-Vangl1 $n=4$, $p=0.0421$). Bar graphs
1087 represent the mean \pm sem of experimental replicates (n). Significance was determined by a two-
1088 sided unpaired t -test with Welch's correction.

1089



1091 **Figure 6—figure supplement 1. Supporting materials for Figure 6.** **A** Rac1 activity as a function
1092 of distance in microns from the leading-edge of collectively migrating MCF7 cells stably
1093 expressing Vector ($n=27$ wells), shVangl2-1 ($n=24$ wells), or shVangl2-2 ($n=25$ wells) at 1, 6, and
1094 12 hours of migration, error bars indicate \pm sem. **B,C** Representative example of custom MATLAB
1095 script identifying the leading-edge of a migrating cohort of MCF7 cells (**B**) and binned migrating
1096 cells based on their distance from the edge of the scratch in microns, where color bar indicates
1097 the distance from the leading-edge of the scratch (**C**), scale bars= $25\mu\text{m}$. **D** RhoA activity in MCF7
1098 cells stably expressing the RhoA biosensor and Control at $5\mu\text{m}$ and $100\mu\text{m}$ from the edge the of
1099 scratch ($n=27$, $p=6.02E-06$), significance was determined by a two-sided paired t -test.

1100 **Supplementary Video 1. RhoA-FRET biosensor video of MCF7-Control.** Representative
1101 videos of spatial activity profiles of RhoA in collectively migrating MCF7 cells stably expressing
1102 RhoA-FRET biosensor for Control over 12 hours. Color bars indicate the range of RhoA-FRET
1103 biosensor ratios. Scale bar=25 μ m.

1104 **Supplementary Video 2. RhoA-FRET biosensor video of MCF7-shVangl2-1.** Representative
1105 videos of spatial activity profiles of RhoA in collectively migrating MCF7 cells stably expressing
1106 RhoA-FRET biosensor for shVangl2-1 over 12 hours. Color bars indicate the range of RhoA-
1107 FRET biosensor ratios. Scale bar=25 μ m.

1108 **Supplementary Video 3. RhoA-FRET biosensor video of MCF7-shVangl2-2.** Representative
1109 videos of spatial activity profiles of RhoA in collectively migrating MCF7 cells stably expressing
1110 RhoA-FRET biosensor for shVangl2-2 over 12 hours. Color bars indicate the range of RhoA-
1111 FRET biosensor ratios. Scale bar=25 μ m.

1112
1113 **Immunoblot Source Files.** The raw data corresponding to Figures 2D, 3E and 3G, and Figure
1114 2-figure supplement 1C, Figure 3-figure supplements 1A and 1B, and Figure 4-figure
1115 supplements 1A and 1B, are compiled in eight folders. Regions of blots included in figures are
1116 indicated by red boxes in two Word documents.